These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36305888)

  • 1. Dichotomic response patterns to PD-1 blockade with cemiplimab in a patient with multiple squamous cell carcinomas.
    Bazzacco G; Zelin E; Toffoli L; Conforti C; di Meo N; Fedele D; Zalaudek I
    J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):e547-e549. PubMed ID: 36305888
    [No Abstract]   [Full Text] [Related]  

  • 2. Cemiplimab in cutaneous squamous cell carcinomas (SCC): an overview and a clinical case.
    Ghidini A; Santangelo D; Vaccaro G; Chillura M; Petrelli F
    Oral Oncol; 2022 May; 128():105847. PubMed ID: 35367788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of response and acquired resistance to the programmed death-1 inhibitor pembrolizumab in Stage III metastatic cutaneous squamous cell carcinoma.
    Zalaudek I; Corneli P; Vernoni S; Fedele D; Papa G; Conforti C; Retrosi C; Vezzoni R; Fagotti S; Longone M; Farinazzo E; di Meo N; Pizzichetta MA
    Dermatol Ther; 2019 Nov; 32(6):e13107. PubMed ID: 31595596
    [No Abstract]   [Full Text] [Related]  

  • 4. Cemiplimab in advanced cutaneous squamous cell carcinoma.
    Naik PP
    Dermatol Ther; 2021 Nov; 34(6):e15184. PubMed ID: 34716727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cemiplimab: First Global Approval.
    Markham A; Duggan S
    Drugs; 2018 Nov; 78(17):1841-1846. PubMed ID: 30456447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma.
    Boutros A; Croce E; Tanda ET; Cecchi F; Arecco L; Genova C; Baldelli I; Lambertini M; Raposio E; Del Mastro L; Spagnolo F
    J Geriatr Oncol; 2024 Mar; 15(2):101640. PubMed ID: 37798175
    [No Abstract]   [Full Text] [Related]  

  • 7. Combination regimens and immunologic mechanisms to enhance the efficacy of cemiplimab for cutaneous squamous cell carcinoma.
    Hanania HL; Lewis DJ
    Expert Rev Anticancer Ther; 2022 Feb; 22(2):237-238. PubMed ID: 34918605
    [No Abstract]   [Full Text] [Related]  

  • 8. Cemiplimab for locally advanced cutaneous squamous cell carcinoma: safety, efficacy, and position in therapy panel.
    Lebas E; Marchal N; Rorive A; Nikkels AF
    Expert Rev Anticancer Ther; 2021 Apr; 21(4):355-363. PubMed ID: 33554680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma.
    Keeping S; Xu Y; Chen CI; Cope S; Mojebi A; Kuznik A; Konidaris G; Ayers D; Sasane M; Allen R; Huynh TM; Popoff E; Freeman M; Andria ML; Fury MG; Singh K; Stockfleth E; Challapalli A; Schmults CD
    Future Oncol; 2021 Feb; 17(5):611-627. PubMed ID: 33052055
    [No Abstract]   [Full Text] [Related]  

  • 10. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.
    Villani A; Ocampo-Garza SS; Potestio L; Fabbrocini G; Ocampo-Candiani J; Ocampo-Garza J; Scalvenzi M
    Expert Opin Drug Saf; 2022 Jan; 21(1):21-29. PubMed ID: 34644510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor.
    Chang AL; Kim J; Luciano R; Sullivan-Chang L; Colevas AD
    JAMA Dermatol; 2016 Jan; 152(1):106-8. PubMed ID: 26422398
    [No Abstract]   [Full Text] [Related]  

  • 12. Follow-up on Programmed Cell Death 1 Inhibitor for Cutaneous Squamous Cell Carcinoma.
    Tran DC; Colevas AD; Chang AL
    JAMA Dermatol; 2017 Jan; 153(1):92-94. PubMed ID: 27784038
    [No Abstract]   [Full Text] [Related]  

  • 13. PD-1 blockade in patients with advanced cutaneous squamous-cell carcinoma and concurrent chronic lymphocytic leukaemia : a case series and literature review.
    Eglmeier J; Debus D; Schultz ES
    Eur J Dermatol; 2020 Feb; 30(1):69-71. PubMed ID: 32250263
    [No Abstract]   [Full Text] [Related]  

  • 14. Prolonged Response to Pembrolizumab in Spindle Cell Squamous Cell Carcinoma Metastatic to the Central Nervous System.
    Liu Y; Fitzgerald B; Perry E; Pathak A; Chao HH
    J Investig Med High Impact Case Rep; 2019; 7():2324709619850216. PubMed ID: 31132886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term survival after anti-PD-1 discontinuation in advanced cutaneous squamous cell carcinoma (cSCC): a proof of concept of benefit of concomitant cemiplimab and radiotherapy.
    Bailly-Caillé B; Levard R; Kottler D; Dompmartin A; L'Orphelin JM
    Cancer Immunol Immunother; 2024 May; 73(7):118. PubMed ID: 38713217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance of clinical response after short treatment with cemiplimab for advanced squamous cell carcinoma.
    Conforti C; Toffoli L; Agozzino M; Fedele D; Moroso S; di Meo N; Zalaudek I
    J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):e443-e445. PubMed ID: 35037322
    [No Abstract]   [Full Text] [Related]  

  • 17. Unresectable auricular squamous cell carcinoma with locoregional metastasis: use of cemiplimab in an immunosuppressed patient.
    França TF; Gontijo JRV; Junior EFV; Lima EM
    An Bras Dermatol; 2024; 99(1):158-160. PubMed ID: 37652819
    [No Abstract]   [Full Text] [Related]  

  • 18. Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios.
    Akhtar K; Sravanthi MV; D'Angelo J; Sivapiragasam A
    J Investig Med High Impact Case Rep; 2022; 10():23247096221121408. PubMed ID: 36017984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant cemiplimab induces durable complete response in locally advanced cutaneous squamous cell carcinoma.
    Geidel G; Adam L; Rünger A; Menz A; Kött J; Haalck T; Gebhardt C
    J Eur Acad Dermatol Venereol; 2023 Dec; 37(12):e1414-e1416. PubMed ID: 37458533
    [No Abstract]   [Full Text] [Related]  

  • 20. Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma.
    Baggi A; Quaglino P; Rubatto M; Depenni R; Guida M; Ascierto PA; Trojaniello C; Queirolo P; Saponara M; Peris K; Spagnolo F; Bianchi L; De Galitiis F; Potenza MC; Proietti I; Marconcini R; Botticelli A; Barbieri V; Licitra L; Alfieri S; Ficorella C; Cortellini A; Fargnoli MC; Troiani T; Tondulli L; Bossi P
    Eur J Cancer; 2021 Nov; 157():250-258. PubMed ID: 34536948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.